Abstract | BACKGROUND: OBJECTIVE: To summarize the clinical trials involving taribavirin and its potential role in the treatment of chronic HCV. METHODS: CONCLUSION:
Taribavirin may increase adherence to therapy for chronic HCV by reducing the need for dose reduction due to anemia. A recent Phase II trial investigating early and sustained virological response showed no statistically significant differences between ribavirin 1000/1200 mg and taribavirin at 800-, 1200-, or 1600-mg dosing, while illustrating a lesser degree of anemia in 800- and 1200-mg dosing of taribavirin. Ongoing studies will continue to examine the efficacy of combination therapy with taribavirin in the place of ribavirin.
|
Authors | Keith R Kearney, James J Thornton, Victor J Navarro |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 9
Issue 18
Pg. 3243-9
(Dec 2008)
ISSN: 1744-7666 [Electronic] England |
PMID | 19040344
(Publication Type: Journal Article, Review)
|
Chemical References |
- Prodrugs
- Ribavirin
- taribavirin
|
Topics |
- Anemia
(chemically induced)
- Animals
- Clinical Trials, Phase II as Topic
- Clinical Trials, Phase III as Topic
- Hepatitis C, Chronic
(drug therapy, virology)
- Humans
- Prodrugs
(adverse effects, pharmacokinetics, therapeutic use)
- Ribavirin
(adverse effects, analogs & derivatives, therapeutic use)
- Treatment Outcome
|